Effect Analysis Of EGFR-TKIs Or Chemotherapy Combined With Radiotherapy In The Treatment Of Brain Metastases Of EGFR Mutant Non-small Cell Lung Cancer

Objective:This paper examines the curative effects and adverse reactions of EGFRTKIs combined with radiotherapy,based on a retrospective analysis of cases of brain metastasis from EGFR mutant non-small cell lung cancer.Methods:51 clinical cases of brain metastasis from EGFR mutant non-small cell lung cancer at our hospital between January 2015 and September 2018 were selected for a retrospective analysis.Patients were divided into two groups based on different treatment plans: 31 cases in the treatment group with EGFR-TKIs combined with brain radiotherapy,and 20 cases in the control group with chemotherapy combined with brain radiotherapy.Any and all measurable lesions with the patients were evaluated for effect using CT or MRI.The curative effects were measured according to Response Evaluation Criteria in Solid Tumors,and adverse reactions according to the WHO criteria of toxic and adverse reactions to anti-cancer drugs.All patients were tracked via outpatient care,hospitalization or phone interviews,and their treatment progress,objective response rate(ORR),disease control rate(DCR),as well as adverse reactions were compared and chisquare tested.α=0.05 was the testing standard,and statistical significance was indicated when P<0.05.Results: After three months of targeted therapy with the treatment group and four weeks of chemotherapy with the control group,the ORR and the DCR of intracranial and systemic lesions were evaluated to be higher in the treatment group,indicating a statistical significance(P<0.05).Adverse reactions in both control and treatment groups during therapy were within tolerable range(below level IV).The most common side effect within the EGFR-TKIs treatment group was rash,with an incidence rate of32.26%,which was much higher than in the control group,indicating a statistical significance in discrepancy(P < 0.05).However,the incidence rate of bone marrow depression and gastrointestinal reactions were much higher in the chemotherapy control group,also bearing statistical significance(P<0.05).Conclusion:For patients of brain metastasis from EGFR mutant non-small cell lung cancer,the EGFR-TKIs targeted therapy combined with cephalic radiotherapy proves to be significantly effective in improving the ORR and the DCR of intracranial and systemic lesions,with relatively low incidence rate of toxic or adverse reactions,whichis a relatively safe and tolerable treatment that warrants wider application in clinical practices.